載入...
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
BACKGROUND. Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10–20%) of febrile neutropenia. Primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) is not routinely recommended by the treatment gui...
Na minha lista:
| 發表在: | Radiol Oncol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Versita, Warsaw
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4387994/ https://ncbi.nlm.nih.gov/pubmed/26029029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2014-0050 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|